AMS-17
Based on 1 Customer Validation
AMS-17 is a potent NLRP3 inhibitor, inhibiting microglia activation in vitro and in vivo. AMS-17 also inhibits cytokines such as caspase-1, TNF-α, IL-1β and inducible nitric oxide synthase (iNOS) in N9 cells. AMS-17 can be used for researching inflammation-associated neurological disorders, such as vascular dementia (VaD).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.09%
- CAS No.: 3019885-78-7
- Formule: C15H13F3N4O3S
- Masse moléculaire:386.35
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
NF-κB Signaling Compound Library
HY-L014
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Pyroptosis Compound Library
HY-L059
-
Antidepressant Compound Library
HY-L108
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Inflammasomes related Compound Library
HY-L175
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Pattern Recognition Receptors Library
HY-L237
Activité biologique
|
NLRP3 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:10-month-old male C57BL/6J mice bearing bilateral common carotid artery stenosis (BCAS) surgery[2].
-
Dosage:20 mg/kg
-
Administration:i.p; daily; 5 consecutive days
-
Result:Improved Cognitive Function: Rescued cognitive deficits in VaD mice.
Protected Brain Structure: Enhanced blood-brain barrier (BBB) integrity, promoted remyelination, and reduced neurodegeneration.
Inhibited NLRP3 Inflammasome Activation: Significantly decreased expression of NLRP3, ASC, and cleaved caspase-1 in the mice brain.
Modulated Inflammatory Cytokines: Reduced systemic pro-inflammatory cytokine levels (TNF-α, IL-1β) while elevating the anti-inflammatory cytokine IL-4 in the mice blood.
Chemical Information
-
CAS No. 3019885-78-7
-
Appearance Solid
-
Masse moléculaire 386.35
-
Formule C15H13F3N4O3S
-
Color White to off-white
-
SMILES
O=C1N(CCCN1S(=O)(C2=CC=C(C=C2)C(F)(F)F)=O)C3=CN=CN=C3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 100 mg/mL (258.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Zhang C, et al. Targeting NLRP3 signaling by a novel-designed sulfonylurea compound for inhibition of microglial inflammation. Bioorg Med Chem. [Content Brief]
[2]. Akif A, et al. Targeting NLRP3 signaling with a novel sulfonylurea compound for the treatment of vascular cognitive impairment and dementia. Fluids Barriers CNS. 2025 Jun 3;22(1):55. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5883 mL | 12.9416 mL | 25.8833 mL | 64.7082 mL |
| 5 mM | 0.5177 mL | 2.5883 mL | 5.1767 mL | 12.9416 mL | |
| 10 mM | 0.2588 mL | 1.2942 mL | 2.5883 mL | 6.4708 mL | |
| 15 mM | 0.1726 mL | 0.8628 mL | 1.7256 mL | 4.3139 mL | |
| 20 mM | 0.1294 mL | 0.6471 mL | 1.2942 mL | 3.2354 mL | |
| 25 mM | 0.1035 mL | 0.5177 mL | 1.0353 mL | 2.5883 mL | |
| 30 mM | 0.0863 mL | 0.4314 mL | 0.8628 mL | 2.1569 mL | |
| 40 mM | 0.0647 mL | 0.3235 mL | 0.6471 mL | 1.6177 mL | |
| 50 mM | 0.0518 mL | 0.2588 mL | 0.5177 mL | 1.2942 mL | |
| 60 mM | 0.0431 mL | 0.2157 mL | 0.4314 mL | 1.0785 mL | |
| 80 mM | 0.0324 mL | 0.1618 mL | 0.3235 mL | 0.8089 mL | |
| 100 mM | 0.0259 mL | 0.1294 mL | 0.2588 mL | 0.6471 mL |
AMS-17 Related Classifications
HY-146765 Related Classifications
Powered by Bioz